Luminex Discloses GenturaDx Loss of $19.8M in 2011, $18.5M in H1 2012

Sep 18, 2012

|

NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.

In a document filed with the US Securities and Exchange Commission, Luminex said that for full-year 2011, GenturaDx recorded no revenues and a net loss of $19.8 million. The company spent $10.1 million on R&D and $3.5 million on SG&A.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Harder to Breathe

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

Sequence From the Jomon Period

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Shifting Sands of Gene Variant Interpretation

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

This Week in Science

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.

Featured White Papers

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

May

21

Featured Webinar

Implementation of qPCR Mutation Assays for Routine Use in a Hematology/Oncology Lab

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

May

22

Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

Jun

17

Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Menu